Soft Tissue Sarcoma

• FDA label_change · 2025-01-03
  FDA Approved: DOXORUBICIN HYDROCHLORIDE — Supplemental Application (Zydus Lifesciences Limited)

  FDA approved a supplemental application for doxorubicin hydrochloride from Zydus Lifesciences Limited, updating the labeling for the product…

• FDA label_change · 2024-05-20
  FDA Approved: PAZOPANIB — Supplemental Application (Apotex Corp.)

  FDA approved a supplemental application for pazopanib by Apotex Corp. (ANDA 217713), likely involving labeling or other post-approval change…

• EMA label_change · 2020-07-24
  Authorised uses of cancer medicine Yondelis unchanged following review of new data

  The EMA review concluded that the authorised uses of Yondelis (trabectedin) remain unchanged after evaluating new data.

• FDA label_change · 2011-10-21
  FDA Approved: VOTRIENT — Supplemental Application (Novartis Pharmaceuticals Corporation)

  FDA approved a supplemental application for VOTRIENT (pazopanib hydrochloride) from Novartis Pharmaceuticals Corporation, resulting in chang…